摘要
目的 :探讨万古霉素治疗重症G+ 菌感染的有效性和安全性。方法 :对 32例耐甲氧西林金葡球菌(MRSA)、耐甲氧西林凝固酶阴性葡萄球菌 (MRCON)和肠球菌所致的重症感染患者 ,给予万古霉素 5 0 0mg ,q8h或q6h ,疗程至少 1周 ,观察其治疗效果和不良反应发生率。 结果 :万古霉素治疗重症G+ 菌感染的总临床有效率为84.38% (2 7/ 32 ) ,细菌清除率 79.10 % (34 / 43) ,不良反应总发生率 9.38% (3/ 32 ) ,其中肾毒性 2例 ,药物热 1例 ,均未经特殊处理 ,停药后恢复正常。结论 :万古霉素是治疗MRSA/MRCON和肠球菌所致重症感染包括败血症、肺部感染。
Objective:To evaluate the efficacy and safety of vancomycin(Vancocin )for treatment of methicillin resistant staphylococcus aureus (MRSA),methicillin resistant coagulase negative staphylococcus (MRCON) and entrococci infections.Methods:32 patients with severe infections of MRSA,MRCON and enterococci were treated with Vancocin 500mg/8h or 500mg/6h for at least 1 week to observe the efficacy and incidence rate of ADRs.Reasults:The total effective rate,bacterial clearance rate,and incidence of ADRs of Vancocin were 84.38%(27/32),79.10%(34/43),and 9.38% (3/32) respectively.Conclusion:Results of the study showed that Vancocin is an effective,relatively safe antibiotic for treatment of severe infections including septicemia,low respiratory tract infections,pneumonia,skin,and soft tissue infection due to MRSA,MRCON and entrococci.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2001年第8期615-617,共3页
Chinese Journal of New Drugs
关键词
万古霉素
耐甲氧西林金葡球菌
耐甲氧西林凝固酶阴性葡萄菌
肠球菌
有效性
安全性
药理
vancomycin
methicillin resistant staphylococcus aureus/methicillin resistant coagulase negative staphylococcus
entrococci
efficacy
safety
